Table 1. Prevalence of recurrent genomic alterations across prostate cancer disease states in published cohorts.

Data was extracted from cBioPortal (https://www.cbioportal.org) except for Quigley et al, Cell 2019(46), where data was extracted from the publication. Percentages rounded except if <0.5%.

			TCGA, Cell 2015	Abida et al, JCO-PO 2017			Abida et al, PNAS 2019	Quigley et al, Cell 2019
		n	333	200	140	164	444*	101
		NGS assay	WES	Panel (MSK-IMPACT)	Panel (MSK-IMPACT)	Panel (MSK-IMPACT)	WES	WGS
		Population	Locoregional PC	Locoregional PC	Hormone-sensitive metastatic PC	mCRPC	mCRPC	mCRPC
	Gene	Alterations	Percentage altered
AR and ERG	AR	Mut, Amp	1	2	4	51	59	70
	ERF	Mut, HomDel	2	0	0	0	5	N/A
	ERG	Fusion	46	N/A	N/A	N/A	41	43
	ETV1	Fusion	9	N/A	N/A	N/A	6	10
	ETV4	Fusion	5	N/A	N/A	N/A	4	5
	ETV5	Fusion	0	N/A	N/A	N/A	0,4	2
	FOXA1	Mut	4	15	10	10	9	19
Cell Cycle	CDK1NB	Mut	2	1	2	7	5	7
	CDKN2A	Mut	2	2	2	2	3	N/A
	RB1	Mut, HomDel	1	2	7	18	13	12
	TP53	Mut, HomDel	8	27	30	48	40	57
DNA repair	ATM	Mut, HomDel	6	2	2	11	7	6
	BRCA1	Mut, HomDel	1	1	1	2	2	1
	BRCA2	Mut, HomDel	3	6	7	10	11	10
	CDK12	Mut, HomDel	2	4	6	10	7	3
	FANCA	Mut, HomDel	8	1	3	7	1	N/A
	MLH1	Mut, HomDel	0,3	1	2	1	1	1
	MSH2	Mut, HomDel	1	0	2	3	2	2
	MSH6	Mut, HomDel	1	0	1	1	2	1
	PALB2	Mut, HomDel	0,3	1	0	3	1	N/A
PI3K	AKT1	Mut	1	0	2	1	1	2
	PIK3CA	Mut	2	3	4	3	3	1
	PIK3CB	Mut	1	0	1	3	2	N/A
	PTEN	Mut, HomDel	17	11	17	27	32	45
WNT	APC	Mut, HomDel	5	3	13	14	8	9
	CTNNB1	Mut	2	2	6	3	4	6
Other	ARID1A	Mut	1	1	1	2	3	N/A
	BRAF	Mut	4	2	2	3	7	4
	CHD1	Mut, HomDel	7	N/A	N/A	N/A	7	9
	MYC	Amp	7	2	6	10	23	33
	SPOP	Mut	11	12	11	5	6	5

^*The denominator for assessment of ERG, ETV1, ETV4 and ETV5 fusions is 266, corresponding only to patients with both WES and RNAseq data available.